Corrigendum: Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients

Front Oncol. 2023 Apr 19:13:1170066. doi: 10.3389/fonc.2023.1170066. eCollection 2023.

Ping Chen¹, Haolin Song², Wei Xu³, Jin Guo⁴, Jianfei Wang⁵, Juhong Zhou⁵, Xiang Kang⁵, Chaolei Jin⁶, Yubo Cai^{7

8

9}, Zixuan Feng⁴, Hainv Gao¹, Fengmin Lu^{10

11}, Lanjuan Li^{7

8

9}

¹ Department of Infectious Diseases, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, China.
² College of Medicine, Zhejiang University, Hangzhou, China.
³ College of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
⁴ Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
⁵ Research and Development Division, Oriomics Biotech Inc, Hangzhou, China.
⁶ Infection and Immunity Institute and Translational Medical Center of Huaihe Hospital, Henan University, Kaifeng, China.
⁷ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
⁸ National Clinical Research Center for Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
⁹ Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
¹⁰ Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
¹¹ Hepatology Institute, Peking University People's Hospital, Beijing, China.

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.1037742.].

Keywords: DCP; GAADPB; GALAD; alpha-fetoprotein; hepatocellular carcinoma.